Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy
| Autor: | F. Stephen Hodi, Zsolt Szabo, Howard L. Kaufman, J. Randolph Hecht, Igor Puzanov, Kevin J. Harrington, Swami Murugappan |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Oncology
medicine.medical_specialty Skin Neoplasms medicine.medical_treatment Herpesvirus 1 Human Targeted therapy Cancer immunotherapy Internal medicine medicine Animals Humans Pharmacology (medical) Melanoma Neoplasm Staging Randomized Controlled Trials as Topic Oncolytic Virotherapy business.industry Cancer Granulocyte-Macrophage Colony-Stimulating Factor Immunotherapy medicine.disease Oncolytic virus Oncolytic Viruses Immunology Oncolytic Virus Therapy Talimogene laherparepvec business |
| Zdroj: | Expert review of anticancer therapy. 15(12) |
| ISSN: | 1744-8328 |
| Popis: | Tumor immunotherapy is emerging as a promising new treatment option for patients with cancer. T-VEC is an intralesional oncolytic virus therapy based on a modified herpes simplex virus type-1. T-VEC selectively targets tumor cells, causing regression in injected lesions and inducing immunologic responses that mediate regression at uninjected/distant sites. In a randomized phase III trial, T-VEC met its primary endpoint of improving the durable response rate vs granulocyte-macrophage colony-stimulating factor in patients with unresectable melanoma. Responses were observed in injected and uninjected regional and visceral lesions. Exploratory analyses suggested survival differences in favor of T-VEC in patients with untreated or stage IIIB/IIIC/IVM1a disease. T-VEC was generally well tolerated, the most common adverse events being flu-like symptoms. Here, we overview recent advances in cancer immunotherapy, focusing on the clinical development of T-VEC, from first-in-human studies and studies in other cancer types, to ongoing combination trials with checkpoint inhibitors. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|